Arjun Prasad - 02 Jan 2026 Form 4 Insider Report for Compass Therapeutics, Inc. (CMPX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: CMPX
Reported as of: 02 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2026, 16:33:32 UTC
Source filing: View source filing
Reporting owner signature: /s/ Neil Lerner, Attorney-in-fact

Key filing fact

Arjun Prasad filed Form 4 for Compass Therapeutics, Inc. (CMPX) on 05 Jan 2026.

Key facts

This page summarizes Arjun Prasad's Form 4 filing for Compass Therapeutics, Inc. (CMPX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2026, 16:33.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002102138 Primary reporting owner

Prasad Arjun

Relationship: Chief Commercial Officer
Address: C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON
Signature: /s/ Neil Lerner, Attorney-in-fact
Signature date: 05 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CMPX transaction Derivative

STOCK OPTION (RIGHT TO BUY)

Award

Transaction value: $0
Shares: +1,000,000
Change %
Price: $0.000000
Shares after: 1,000,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: COMMON STOCK
Underlying amount: 1,000,000
Exercise price: $5.17
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options were granted pursuant to the Compass Therapeutics, Inc. 2025 Inducement Plan as a material inducement to the Reporting Person's acceptance of employment with the Issuer in accordance with Nasdaq Rule 5635(c)(4).

Footnote F2

The options will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on January 2, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments thereafter.